Subversive Acquisition LP (OTCQX: SBVRF) gave the market an update on its qualifying transaction (QT) to combine with Israeli-based InterCure Ltd. Subversive believes the deal will close on April 8, 2021. InterCure is the first public company on the Tel Aviv Stock Exchange to hold a valid and permanent license for the medical cannabis value chain through its 100% ownership in Canndoc. Canndoc is a GMP medical cannabis producer and was licensed by the Israeli Ministry of Health in 2008. It is a leading pioneer in the research, cultivation, production, and distribution of pharma-grade cannabis-based products to patients, hospitals, pharmacies, research, and governmental organizations. Through its strategic exclusive collaboration with world leaders, distribution agreement with SLE ( and long-term sales agreements, Canndoc is well-positioned as a leading and significant player in pharma-grade medical cannabis in Israel, Europe, and the United Kingdom.
Rahim Rad, Green Market Report, 03/29/2021 08:54:00
Open article: https://www.greenmarketreport.com/subversive-expects-israeli-intercure-deal-to-close-in-april/?utm_source=rss&utm_medium=rss&utm_campaign=subversive-expects-israeli-intercure-deal-to-close-in-april